Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;96(11):e70017.
doi: 10.1002/jmv.70017.

Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study

Yu Zhai  1   2 , Haopeng Li  1 , Peng Xia  3 , Yunfei Jiang  2 , Hanwen Tong  2 , Dongming Zhou  4 , Chenxiao Jiang  5 , Yun Liu  2 , Jun Wang  1   2
Affiliations

Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study

Yu Zhai et al. J Med Virol. 2024 Nov.

Abstract

Intravenous immunoglobulin (IVIG) is frequently administered to patients with severe fever with thrombocytopenia syndrome (SFTS), particularly those with severe manifestations, although its efficacy remains controversial. The study retrospectively analyzed the effects of IVIG administration on SFTS patients in both mild and severe groups. The primary outcome measure was 28-day mortality. Inverse probability of treatment weighting (IPTW) with propensity score was used to account for baseline confounders. A total of SFTS patients with complete data enrolled from January 1, 2015, to August 1, 2023. Death at 28 days occurred for 68 (17.5%) patients. By unadjusted analysis, no difference was observed for 28-day mortality between the IVIG and non-IVIG groups in both the mild and severe groups. Similar results were found by propensity score matching and by IPTW analysis. Although IVIG is frequently used as adjuvant therapy for severe SFTS patients, no significant association was observed between IVIG treatment and reduced mortality in this patient population.

Keywords: intravenous immunoglobulin; mild and severe group; mortality; severe fever with thrombocytopenia syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the research. IVIG, intravenous immunoglobulin; SFTS, severe fever with thrombocytopenia syndrome.
Figure 2
Figure 2
Kaplan–Meier analysis for 28‐day survival of the IVIG and non‐IVIG groups in the severe group. IVIG, intravenous immunoglobulin.
See this image and copyright information in PMC

References

    1. Saijo M. Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy. J Infect Chemother. 2018;24(10):773‐781. - PubMed
    1. Guo CT, Lu QB, Ding SJ, et al. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome (SFTS) in China: an integrated data analysis. Epidemiol Infect. 2016;144(6):1345‐1354. - PubMed
    1. Li H, Lu QB, Xing B, et al. Epidemiological and clinical features of laboratory‐diagnosed severe fever with thrombocytopenia syndrome in China, 2011‐17: a prospective observational study. Lancet Infect Dis. 2018;18(10):1127‐1137. - PubMed
    1. Cui N, Liu R, Lu QB, et al. Severe fever with thrombocytopenia syndrome bunyavirus‐related human encephalitis. J Infect. 2015;70(1):52‐59. - PubMed
    1. Fujikawa K, Koga T, Honda T, et al. Serial analysis of cytokine and chemokine profiles and viral load in severe fever with thrombocytopenia syndrome: case report and review of literature. Medicine. 2019;98(42):e17571. - PMC - PubMed

Substances

LinkOut - more resources